The importance of nitric oxide (NO) for CBF variations associated with arterial carbon dioxide changes was investigated in halothane-anesthetized rats by using an inhibitor of nitric oxide synthase, NJ-nitro-L-arginine (NOLAG). CBF was measured by intracarotid injection of 133Xe. In normocapnia, intracarotid infusion of 1.5, or 7.5, or 30 mg/kg NOLAG induced a dose-dependent in crease of arterial blood pressure and a decrease of nor mocapnic CBF from 85 ± 10 to 78 ± 6, 64 ± 5, and 52 ± 5 ml l00g -I min -I, respectively. This effect lasted for at
least 2 h. Raising P aco 2 from a control level of 40 to 68 mm Hg increased CBF to 230 ± 27 ml 100g -I min -I , correspopdiRg to a percentage CBF response (C0 2 reac tivity) C!l3.7 ± 0.6%/mm Hg P aco 2 in saline-treated rats.
NOLAG att enuated this reactivity by 32, 49, and 51% at the three-dose levels. Hypercapnia combined with an giotensin to raise blood pressure to the same level as the The endothelium-derived relaxing factor nitric oxide (NO) or a closely related NO-containing com pound (Ignarro et aI., 1987; Palmer et aI., 1987) is currently being studied intensively. In vitro studies have shown that the amino-nitrogen of the guani dino group of L-arginine is the precursor (Palmer et aI., 1988a; Sakuma et aI., 1988; Schmidt et aI., 1988) . NO synthase is also located in the brain tis sue as well as in perivascular nerves (Bredt et aI., highest dose of NO LAG did not affect the CBF response to hypercapnia. L-Arginine significantly prevented the ef fect of NOLAG on normocapnic CBF as well as blood pressure and also abolished its inhibitory effect on hyper capnic CBF. o-Arginine had no such effect. Decreasing p aco 2 to 20 mm Hg reduced control CBF to 46 ± 3 ml lOOg -1 min-I with no further reduction after NOLAG. Furthermore, NOLAG did not change the percentage CBF response to an extracellular acidosis induced by ac etazolamide (50 mg/kg). The results suggest that NO or a closely related compound is involved in the regulation of CBF in normocapnia and even more so in hypercapnia. Key Words: Acetazolamide-Carbon dioxide-Cerebral blood flow-Hypercapnic cerebral vasodilatation Hypocapnia-Nitric oxide-NG-Nitro-L-arginine Normocapnia. 1990) where it forms NO from L-arginine in a very similar manner as in the endothelium (Knowles et aI., 1989; Moncada et aI., 1989 ). With use of suit able doses of modified forms of L-arginine, in which the active group is no longer chemically active in the reaction, it is possible to block NO synthesis. � -Monomethyl-L-arginine (L-NMMA) and � nitro-L-arginine (NOLAG) have been found to act in this way in endothelium (Palmer et aI., 1988b; Rees et aI., 1989a; Moore et aI., 1990) as well as in brain tissue (Bredt and Snyder, 1989; Garthwaite et aI., 1989a,b; Knowles et aI., 1989; Forstermann et aI., 1990; Murphy et aI., 1990) . They both block NO synthase reversibly, an effect that can be counter acted competitively by administering large doses of L-arginine, while n-arginine has no effect (Palmer et aI., 1988b; Garthwaite et aI., 1989b; Rees et aI., 1989a; Moore et aI., 1990) .
We here report studies of the effect of NOLAG on the CBF in hypo-, normo-, and hypercapnia. NOLAG was found to reduce normocapnic CBF and even more markedly to attenuate the hypercap nic CBF increase, but it had no effect on hypocap nia or on the CBF response to extracellular acidosis induced by acetazolamide.
MATERIALS AND METHODS

Animal preparation
The experiments were performed on 117 male Wi star rats weighing 300-350 g (M�llegaard Ltd., Denmark). An esthesia was induced with 4% halothane and maintained with 0.7% halothane in 30% oxygen170% N 2 0 during the operation and with 0.6% halothane in 0 2 /N 2 0 after the operation. The animals were tracheostomized, immobi lized with suxamethonium (40 mg/kg), and artificially ventilated by a rodent respirator. The scalp over the right hemisphere of the brain was removed, and the right tem poral muscle was loosened from the cranium and flapped down to avoid extracranial deposition of injected 133Xe within the field of view of the detector. Both femoral arteries were cannulated (PE-50) to allow continuous blood pressure recording and collection of blood samples. Both femoral veins were cannulated as well and used for drug and donor blood supplement. All extracerebral branches of the right common carotid artery were ligated, including the pterygopalatine artery, to minimize the ex tracerebral distribution of 133Xe. The animals were hep arinized (3,000 IU /kg) prior to ligation of the pterygopala tine artery. Finally, the external carotid was cannulated (PE-25) with the catheter tip close to the carotid bifurca tion and used for bolus injection of 133Xe and for nitro-L arginine infusion.
Arterial P aco2' Po2, and pH were recorded at each CBF measurement (ABL 30; Radiometer, Copenhagen, Denmark). Arterial P a02 was kept above 100 mm Hg in all studies. In the control series, P aco2 was 38-40 mm Hg and pH 7.37-7.42. All blood samples collected were re placed with donor blood from rats of the same strain. The arterial blood pressure was continuously followed during the study by using a conventional capacitance manome ter. Body temperature was maintained close to 37°C by a rectal thermostatic controller connected to a heating pad.
For measurement of CBF, the intracarotid 133Xe method as adapted for small rodents (Hertz et aI., 1977) was used. CBF was determined from the 10-to 15-s ini tially steepest slope of the semilogarithmic clearance curve recorded from the rate meter analog output after injection of a 10-to 60-I.Ll bolus of 133Xe dissolved in saline (10 mCilml; Amersham).
Protocol
In one group of rats, we measured the effect of NOLAG on the basal and CO 2 -stimulated CBF. CBF was first measured at normocapnia 12 min after ending the intracarotid infusion of saline, 0.6 ml over 6 min. Then hypercapnia was induced by adding 5% CO 2 to the in spired gas, and CBF was measured after steady state had been reached. Thereafter, CO 2 breathing was stopped and a dose of 1.5 or 7.5 mg/kg NOLAG was infused in-J Cereb Blood Flow Metab, Vol. 12, No.6, 1992 tracarotidly at a rate of 0,1 ml/min for 6 min. CBF was studied 12 min later in normocapnia and subsequently in hypercapnia. In another six rats, a dose of 30 mg/kg NOLAG was given intracarotidly with a speed of 0.1 mil min for 25 min (7.5 mg/kg NOLAG is the maximal dose to be dissolved in 0.6 ml saline ultrasonically) to test the effect of a high dose of NOLAG on normocapnia and hypercapnia. As NOLAG increases systemic blood pres sure quite markedly, we also included a second control group of five rats in which blood pressure was elevated by an infusion of angiotensin (2-3 x 10 -5 mg/min) to reach the same pressure level as with the highest dose of NOLAG.
In second group of rats, hypocapnia was induced by hyperventilating the animals to a P ac02 of 20 mm Hg.
After a stable hypocapnic level had been reached, control CBF was measured. Thereafter 7.5 mg/kg NOLAG was infused intracarotidly at a rate of 0.1 mllmin over 6 min during hypocapnia. CBF was then measured again 12 min after infusion.
In two separate groups of rats, an intravenous bolus of L-or o-arginine (150 mg/kg) was given followed by a 100mg/kg/h (0.05-mllmin) infusion before the application of 7.5 mg/kg NOLAG. This was done to test whether the inhibitory effect of NOLAG on normo-and hypercapnic CBF could be antagonized by L-arginine and D-arginine.
In a fifth group of rats, the effect of NOLAG on an acetazolamide-induced CBF increase (Severinghaus and Cotev, 1968; Vorstrup et aI., 1984) was tested. After 7.5 mg/kg NOLAG (control animals were treated by saline), a 50-mg/kg dose of acetazolamide was injected subcuta neously, and the animals were hyperventilated to keep measured P aco2 at the normocapnic level. CBF was re corded 15-20 min after acetazolamide injection.
In a sixth group of rats, mild hypercapnia (P aco2 = 52 mm Hg) was induced with the purpose of obtaining the same CBF level as that during acetazolamide administra tion. A dose of 7.5 mg/kg NOLAG was given intraca rotidly to test its effect on this hypercapnic CBF level for comparison with the acetazolamide-treated animals.
At end of most experiments, in both saline-and NOLAG-treated animals, 2.5% Evans Blue was given in travenously (2.5 mllkg) to delineate possible major lesions of the blood-brain barrier (BBB). Five minutes later, rats were decapitated and brains were removed and examined for extravasation of the dye.
Drugs
NOLAG [N5-(nitroamidino)-L-2,5-diaminopentanoic acid] was purchased from Aldrich Chemistry Co., acet azolamide from Lederle, and angiotensin from Ciba Geigy. All other compounds were obtained from Sigma. The drugs were dissolved in saline and the NOLAG so lution was ultrasonicated for 5-10 min to dissolve it com pletely in the saline. This solution had a calculated osmo larity of 328 mOsmol and a measured pH of 7.2.
Statistics and calculations
The Mann-Whitney test was used for comparing values under control conditions and during interventions. All values are presented as means ± SD. p < 0.05 was con sidered significant.
The .C02 reacti ,: ity was calculated as �ln CBF/ � P aco2 X 100 III each rat sillce exponential curves give the best fit of the relation between CBP and Paco2 (Olesen et aI., 1971 ).
RESULTS
Effect of NOLAG at normocapnia (p aCoZ = 40 mmHg)
As illustrated in Table 1 and Fig. 1 , NOLAG caused a dose-dependent decrease in normocapnic CBF by 9 ± 7, 23 ± 8, and 32 ± 6% and an increase in blood pressure by 10 ± 6, 38 ± 10, and 52 ± 18% at the dose levels of 1.5, 7.5, and 30 mg/kg, respec tively. In a separate group of four animals, a time course study was performed showing that the ef fects lasted for at least 2 h.
Effect of NOLAG at hypercapnia (p aCoZ adjusted to 68 mm Hg) During hypercapnia, NOLAG caused an even more marked decrease of CBF relative to the saline treated controls. With saline infusion, hypercapnia induced almost a threefold increase in CBF from a normocapnic control level, and the calculated COz reactivity of CBF was 3.7 ± 0.6%/mm Hg PaCO Z ' After NOLAG infusion, the CBF increase was much less (see Table 2 and Fig. 2) , and the calcu lated CO2 reactivity ofCBF was only 2.5 ± 0.5, 1.9 ± 0.4, and 1.8 ± O.4%/mm Hg PaCOZ at the three dose levels. This means that NOLAG reduced the COz reactivity by 32, 49, and 51%, respectively.
As a check on the validity of these data, two ad ditional studies were carried out. In three animals, hypercapnia was repeated several times in the sa line-infused control state. No attenuation of CBF increase or calculated CO2 reactivity was found. In the five saline-infused animals in which blood pres sure was raised to � 150 mm Hg by angiotensin, hypercapnic CBF increased to the same high levels as in the normotensive controls and the calculated CO2 reactivity even rose slightly to 4.2 ± 1 %/mm Hg PaCOZ (see Table 2 ). Effect of NOLAG during hypocapnia (P aCoZ = 20 mmHg)
As shown in Fig. 2 , reducing Pacoz to 20 mm Hg caused a reduction of CBF to 46 ± 3 mill 00 g/min (n = 5). This was not further reduced by 7.5 mg/kg NOLAG because at this dose hypocapnic CBF av eraged 45 ± 3 ml/lOO glmin (n = 5).
Effect of NOLAG when combined with ;lcetazolamide and comparison with mild hypercapnia (P aCoZ = 52 mm Hg)
When hyperventilation was induced to keep the measured P aCoZ constant, the inhibitor of carbonic Values are means ± SD; n = no. of rats. CO 2 reactivity was calculated as �In CBF/�Pacoz x 100 (%/mm Hg). NOLAG, ,yG-nitro L-arginine. a p < 0.05, b p < 0.01, cp < 0.001 vs. saline-treated animals. d p < 0.01, ep < 0.001 vs. 7.5 mg/kg NOLAG-treated animals.
anhydrase acetazolamide raised CBF from a control level of 81 ± 14 to 130 ± 19 ml/l00 g/min, corre sponding to a 61 ± 16% increase in CBF when com paring individual control values. With 7.5 mg/kg NOLAG, the basal and acetazolamide-induced CBF values were both reduced proportionally (see Table 3 ). Thus, relative to the lowered basal CBF level, acetazolamide still elicited the same percent age increase in CBF of 62 ± 17%; i.e., the acetazol amide CBF response was unchanged. Elevating P aco2 to 52 mm Hg was found to in- crease CBF to about the same level as acetazol amide in saline-infused controls, When giving NOLAG at 7.5 mg/kg at this level of hypercapnia, CBF decreased much more than after acetazol amide as the percentage increase in CBF was only 30% (see Table 3 ).
Effect of L-and D-arginine on NOLAG (Fig. 3) The preapplication of L-arginine significantly pre vented the effect of 7.5 mg/kg NOLAG in normo capnia as blood pressure and CBF were close to control levels (Table O . It also completely pre served the response of cerebral vessels to increase P aco2 as hypercapnia increased CBF to 222 ± 45 ml 100g-1 min -I and CO2 reactiv i ty was brought back to 3.6 ± 0.5%, very similar to that of the saline infused controls (3.7 ± 0.6%). In contrast, the de crease in hypercapnic CBF in response to NOLAG was not significantly changed by preapplication of D-arginine. D-Arginine significantly potentiated the effect of NOLAG on MABP, increasing it from 129 ± 9 to 145 ± 15 mm Hg at normocapnia.
Effect of NOLAG on BBB
There was no evidence of damage to the BBB caused by NOLAG, as judged by the lack of visible extravasation of Evans Blue in the brains studied.
DISCUSSION
The method using intracarotid NOLAG infusion was designed to maximize local relative to systemic effects. The effect of NOLAG is, however, almost as marked on the contralateral hemisphere (data not shown). In a few studies infusing NOLAG intrave nously at a dose of 30 mg/kg, essentially the same effects on normo-and hypercapnic CBF were pro duced as by the intracarotid route (data not shown). Values are means ± SD; n = no. of rats. % CBF increase; average values of percentage increase of CBF in each rat. a p < 0. 05 vs. saline-treated animals.
We saw a clear-cut rise in MABP with NOLAG. This agrees with other studies using L-arginine an alogues blocking NO synthase, such as L-NMMA (Aisaka et aI., 1989; Rees et aI., 1989b; Koiniewska et aI., 1992) and NOLAG (Beckman et aI., 1991) . Our finding of enhanced pressor response when D-arginine was combined with NOLAG was unex pected. It seems to be a nonspecific effect caused by the volume of vehicle injected along with the D-arginine, reaching 2.2 ml at the time the effect of NOLAG was studied, because injecting the same volume of vehicle with NOLAG caused the same accentuated hypertension.
At normocapnic Paco2 levels, we found a 23 ± 8 and 32 ± 6% decrease of CBF after intracarotid infusion of 7.5 and 30 mg/kg NOLAG. This is con sistent with Beckman et ai. 's findings (199 1) in nor- mocapnic rats infused intravenously with 30 mg/kg of NOLAG. The decreased basal CBF was also ob served by using another inhibitor of NO, L-NMMA, in different species (Greenberg et aI., 1991; Tanaka et aI., 199 1; Koiniewska et aI., 1992) . The reduced CBF in the face of a clear-cut rise of systemic blood pressure implies a sharp increase in cerebrovascu lar resistance; thus, the arterioles must have been contracted to a considerable degree. Apparently continuous NO production is a necessity for keep ing the cerebral vessels at the relatively low tone characteristic of the normocapnic state. During hypercapnia, CBF increased in the saline infused control state to the expected very high level. This was markedly attenuated by NOLAG in a dose-dependent manner. The inhibitory effect of NOLAG was, as expected, almost completely abol ished by high doses of L-arginine, whereas D-argi niQe had no effect. The depressed CO2 reactivity caused by NOLAG could not be explained by the associated rise in blood pressure, because in an giotensin-infused animals in which the same level of hypertension was reached, the normal CBF re sponse to CO2 was preserved. This is also in agree ment with early studies in humans showing that the response of the CBF to CO2 in elderly hypertensive patients is same as in normal young men (Fazekas et aI., 1953; Novack et aI., 1953) . The intact BBB after NOLAG administration also suggests that its effects are not related to barrier damage.
Nevertheless, one could argue that the markedly depressed CO2 reactivity caused by NOLAG might be secondary to a depression of tissue metabolism. Barbiturates, to give a well-known example, de press the metabolic level of the brain and secondar ily, so it appears, reduce CBF. The fact that NO is produced and exerts effects in the brain tissue should here be mentioned (Knowles et aI., 1989; Garthwaite et aI., 1989a Garthwaite et aI., ,b, 1991 Moncada et aI., 1989; GaIly et aI., 1990; Murphy et aI., 1990) . How ever, studies using L-NMMA (Greenberg et aI., 199 1; Koiniewska et aI., 1992) and NOLAG (Q. Wang et aI., unpublished data) lend no support to this hypothesis as the CMR02 was found not to be reduced. Moreover, a preserved autoregulation of CBF after NOLAG (Wang et al., 1992) also sug gests that the depressed CO2 response caused by NOLAG is not related to interference with cerebral autoregulation.
A possible nonspecific effect of NOLAG on hy percapnia should be mentioned. In this hypothesis, the vasodilatation induced by hypercapnia is not mediated by NO, but depends on other mecha nisms. Yet, only when NO is present, reducing ce rebrovascular tone, will the COz-induced effects have their normal magnitude. Extrapolating, by the biochemical "surgery" of a false substrate, the NO component might result in a decreased CO2 re sponsiveness without NO necessarily being directly involved in the CO2 effect. But, if this were true, we would expect that inhibition of NO should also sup press other cerebral vasodilator responses, such as the one seen with hypoxia. However, Kozniewska et al. 's recent study (1992) showed a preserved hyp oxic cerebral response after NO inhibition, tending to disprove this hypothesis of a nonspecific effect of NOLAG in our study. Thus, it could be concluded that the vasodilation induced by hypercapnia, and already seen at normocapnia when compared with hypocapnia, is at least in part mediated by NO.
If, indeed, the NO concentration of the vessel wall increases during hypercapnia, where does this NO come from? Recent studies suggest that endo thelium-derived factors are not involved as damage of the endothelium in vitro or in vivo was found not to influence the central vasodilator response to CO2 (Gotoh et al., 1987; Toda et al., 1989) . However, the pioneering work of Bredt et al. (1990) has demon strated NO synthase immunoreactivity in neurons and also in perivascular nerves contacting smooth muscles (but not in the smooth muscle cells). An astrocyte-derived vasorelaxing factor with similar properties to those of NO has also been described (Murphy et al., 1990) . These observations imply that other sources of NO must be considered.
Hypercanic central vasodilatation is undoubtedly related to CO2-induced pH changes in and around the smooth muscle cells (Gotoh et al., 1961; Lassen, 1968; Wahl et al., 1970) . NO would seem, at least in part, to be involved in the mechanisms by which these pH changes influence the contractile elements of the vessel wall. With the aim of possibly clarify ing this possibility, the acetazolamide experiments were performed. Acetazolamide results in clear-cut extracellular acidosis in brain, both in spontane ously breathing humans and in hyperventilated an imals, whereas intracellular pH (pHi) is unchanged (Bickler et al., 1988; Vorstrup et al., 1989 ). In con trast, hypercapnia causes acidosis in both compart-J Cereb Blood Flow Metab, Vol. 12, No. 6, 1992 ments (Loeschcke and Ahmad, 1980; Jensen et al., 1988) . After NOLAG infusion, acetazolamide did not increase CBF as much as in the saline-infused controls, but the percentage increase in CBF re mained unchanged. By contrast, in hypercapnia the CBF reduction after NOLAG was much more marked (see Table 3 ). This suggests that the in crease in NO hypothesized above to occur with CO2 should be expected to act on the pHcsensitive com ponent of the CO2 responsiveness. This hypothesis fits with the interesting in vitro study of Heinzel et al. (1992) showing that NO snythase activity from the brain tissue (cerebellum) is quite markedly in fluenced by pH in that acid pH increases NO pro duction. With acetazolamide, pHi is essentially un changed, while with CO2, pHi becomes acid and NO synthesis might therefore be increased.
